Massive NIH–industry project opens portals to target validation

Five years in, the US$360 million Accelerating Medicines Partnership is yielding tools to speed up drug discovery for rheumatoid arthritis, lupus, diabetes, Alzheimer disease and Parkinson disease.
By
  1. Elie Dolgin
    View author publications

    You can also search for this author in PubMed  Google Scholar

Credit: Image modified from normaals/iStock/Getty Images Plus

Access through your institution
Buy or subscribe

In April 2014, Francis Collins stood before a US Congressional committee and touted the creation of an “unprecedented public–private effort” that would use “cutting-edge scientific approaches to sift through a long list of potential therapeutic targets and biomarkers” and ultimately “treat and cure disease faster”.

Access options

Access through your institution

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 18, 240-242 (2019)

doi: https://doi.org/10.1038/d41573-019-00033-8

Updates & Corrections

  • Clarification 01 March 2019: Clarifications have been made about Regeneron's use of the diabetes portal and about the number of exomes needed to account for more of the genetic underpinnings of diabetes.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing